Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM

Conference Correspondent  - ASH Highlights

Efficacy and a manageable safety profile have been demonstrated previously for belantamab mafodotin-blmf (belamaf), an immunoconjugate targeting B-cell maturation antigen with a unique mechanism of action, in patients with relapsed/refractory multiple myeloma (RRMM). The addition of pomalidomide (POM), an immunomodulatory drug, to belamaf is postulated to enhance immune responses through augmentation of T-cell and natural killer cell–mediated immunity. The current multicenter phase 1 dose-escalation and expansion study assessed the maximum tolerated dose, the recommended dose for phase 2 study, safety, tolerability, and efficacy of belamaf + POM + dexamethasone (DEX) in patients with RRMM.

Enrollment criteria included having received ≥1 lines of prior treatment, exposure to lenalidomide and a proteasome inhibitor, and being refractory to the last line of therapy. POM 4 mg was given on days 1 to 21, DEX 40 mg (or 20 mg if aged >75 years) was given weekly, and belamaf intravenous SINGLE regimen (1.95 or 2.5 mg/kg on day 1) or SPLIT regimen (2.5 or 3.4 mg/kg, split equally on days 1 and 8) was given once every 4 weeks. Alternative dosing schedules were also permitted at the 2.5-mg/kg dose, including a 2.5-mg/kg LOADING dose followed by 1.92 mg/kg once every 4 weeks from Cycle 2 on, and 2.5 mg/kg once every 8 weeks or once every 12 weeks. A standard 3+3 dose-escalation design was used.

Thirty-seven patients completed the 28-day dose-limiting toxicity observation period. Dose levels and schedules were as follows: 1.92 mg/kg SINGLE (n = 12), 2.5 mg/kg SINGLE (n = 7), 2.5 mg/kg LOADING (n = 5), 2.5 mg/kg SPLIT (n = 8), and 3.4 mg/kg SPLIT (n = 5). The median age was 64 years, and patients had received a median of 3 prior regimens; 64.9% received prior autologous stem-cell transplant, 100% received prior proteasome inhibitors (PIs; 81.1% refractory), 100% received prior lenalidomide (89.2% refractory), and 43.2% received prior daratumumab (100% refractory). A total of 73% of patients were double-refractory (lenalidomide and a PI), and 35.1% were triple-refractory (lenalidomide, PI, and daratumumab). Nine patients had high-risk cytogenetics.

The most frequent treatment-emergent adverse events (TEAEs) of any grade across all cohorts were keratopathy/microcyst-like epithelial changes (MECs) among 75.7% of patients, fatigue among 40.5%, neutropenia among 56.8%, thrombocytopenia among 48.6%, and fever among 35.1%. The most common grade 3/4 TEAEs were keratopathy/MECs (51.4%), neutropenia (40.5%), thrombocytopenia (32.4%), decreased visual acuity (16.3%), and lung infection (5.4%). Sixteen patients (43.2%) experienced serious adverse events. Three dose-limiting toxicities resulting from ocular events occurred (2.5-mg/kg SINGLE, n = 1; 3.4-mg/kg SPLIT, n = 2). The maximum tolerated dose was therefore determined to be 2.5-mg/kg SINGLE and 2.5-mg/kg SPLIT + POM/DEX doses.

Among 34 patients evaluable for response across all cohorts, the overall response rate was 88%, with 68% achieving very good partial response or better. Progression-free survival for the total population was not reached; however, it was 14.1 months for those receiving 1.92 mg/kg every 4 weeks. Patients received a median of 6 cycles. At data cutoff, 8 patients discontinued treatment (progressive disease, n = 5; patient withdrawal, n = 2; grade 4 decreased visual acuity, n = 1), and 27 continue.

Results from Part 1 of this phase 1 study show promising efficacy for belamaf + POM + DEX, with a safety profile consistent with that previously reported for these agents. However, concern over the high rate of dose holds at the 2.5-mg/kg dose was deemed to warrant examination of alternative dosing schedules. Dose selection for the phase 2 study will be conducted when complete data from the current cohorts become available.


Reference

Abstract 725. ASH 2020. December 7, 2020. Part 1 Results of a Dose Finding Study of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM).

Related Items
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Leukemia, Novel Pharmaceuticals
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelofibrosis, Novel Pharmaceuticals
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Conference Correspondent  published on December 9, 2020 in ASH Highlights
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
AMG 701, a Bispecific T-Cell Engager Molecule, in RRMM: A Phase 1 First-in-Human Study
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.